A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam
Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2
mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs
Inc.®)following a single, oral dose (I x 2 mg disintegrating tablet) in healthy adult
volunteers administered under fasting conditions.